Metabolic profiling using HPLC allows classification of drugs according to their mechanisms of action in HL-1 cardiomyocytes

Toxicology and Applied Pharmacology

Volumn 252, Issue 2, 2011, Pages 183-191

  Strigun, Alexander ^a   Wahrheit, Judith ^a   Beckers, Simone ^a   Heinzle, Elmar ^a   Noor, Fozia ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

Cardiotoxicity; Drug screening; Metabolic footprint analysis; Metabolome; Principal component analysis

Indexed keywords

AMIODARONE; ANALGESIC AGENT; ANTHRACYCLINE DERIVATIVE; ANTIHISTAMINIC AGENT; ANTIMETABOLITE; ASTEMIZOLE; DAUNORUBICIN; DICLOFENAC; DOXORUBICIN; DRUG METABOLITE; FLUOROURACIL; METHOTREXATE; PARACETAMOL; QUINIDINE; TERFENADINE; VERAPAMIL;

ARTICLE; CARDIOTOXICITY; CONTROLLED STUDY; DISCRIMINANT ANALYSIS; DRUG CLASSIFICATION; DRUG MECHANISM; ELECTROPHYSIOLOGY; ENERGY METABOLISM; HEART MUSCLE CELL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; METABOLOMICS; PRINCIPAL COMPONENT ANALYSIS; QUANTITATIVE ANALYSIS; SUPERNATANT; VALIDATION PROCESS;

CELLS, CULTURED; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; METABOLOME; MYOCYTES, CARDIAC; PHARMACEUTICAL PREPARATIONS;

EID: 79953680145     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2011.02.008     Document Type: Article

References (69)

1. Allen J., Davey H.M., Broadhurst D., Heald J.K., Rowland J.J., Oliver S.G., Kell D.B. High-throughput classification of yeast mutants for functional genomics using metabolic footprinting. Nat. Biotechnol. 2003, 21:692-696.
2. Allen J., Davey H.M., Broadhurst D., Rowland J.J., Oliver S.G., Kell D.B. Discrimination of modes of action of antifungal substances by use of metabolic footprinting. Appl. Environ. Microbiol. 2004, 70:6157-6165.
3. Andersson H., Kagedal B., Mandenius C.F. Monitoring of troponin release from cardiomyocytes during exposure to toxic substances using surface plasmon resonance biosensing. Anal. Bioanal. Chem. 2010, 398:1395-1402.
4. Andreadou I., Papaefthimiou M., Zira A., Constantinou M., Sigala F., Skaltsounis A.L., Tsantili-Kakoulidou A., Iliodromitis E.K., Kremastinos D.T., Mikros E. Metabonomic identification of novel biomarkers in doxorubicin cardiotoxicity and protective effect of the natural antioxidant oleuropein. NMR Biomed. 2009, 22:585-592.
5. Armstrong S.C., Cozza K.L. Antihistamines. Psychosomatics 2003, 44:430-434.
6. Ashrafian H., Frenneaux M.P., Opie L.H. Metabolic mechanisms in heart failure. Circulation 2007, 116:434-448.
7. Ashrafian H., Neubauer S. Metabolomic profiling of cardiac substrate utilization: fanning the flames of systems biology?. Circulation 2009, 119:1700-1702.
8. Beger R.D., Sun J., Schnackenberg L.K. Metabolomics approaches for discovering biomarkers of drug-induced hepatotoxicity and nephrotoxicity. Toxicol. Appl. Pharmacol. 2010, 243:154-166.
9. Chaudary N., Naydenova Z., Shuralyova I., Coe I.R. Hypoxia regulates the adenosine transporter, mENT1, in the murine cardiomyocyte cell line, HL-1. Cardiovasc. Res. 2004, 61:780-788.
10. Clarke C.J., Haselden J.N. Metabolic profiling as a tool for understanding mechanisms of toxicity. Toxicol. Pathol. 2008, 36:140-147.
11. Claycomb W.C., Lanson N.A., Stallworth B.S., Egeland D.B., Delcarpio J.B., Bahinski A., Izzo N.J. HL-1 cells: a cardiac muscle cell line that contracts and retains phenotypic characteristics of the adult cardiomyocyte. Proc. Natl Acad. Sci. USA 1998, 95:2979-2984.
12. Darpo B. Detection and reporting of drug-induced proarrhythmias: room for improvement. Europace 2007, 9(Suppl):23-36.
13. Depre C., Taegtmeyer H. Metabolic aspects of programmed cell survival and cell death in the heart. Cardiovasc. Res. 2000, 45:538-548.
14. Dunn W.B., Brown M., Worton S.A., Crocker I.P., Broadhurst D., Horgan R., Kenny L.C., Baker P.N., Kell D.B., Heazell A.E. Changes in the metabolic footprint of placental explant-conditioned culture medium identifies metabolic disturbances related to hypoxia and pre-eclampsia. Placenta 2009, 30:974-980.
15. Floyd J.D., Nguyen D.T., Lobins R.L., Bashir Q., Doll D.C., Perry M.C. Cardiotoxicity of cancer therapy. J. Clin. Oncol. 2005, 23:7685-7696.
16. Fox J.E., Jones L., Light P.E. Identification and pharmacological characterization of sarcolemmal ATP-sensitive potassium channels in the murine atrial HL-1 cell line. J. Cardiovasc. Pharmacol. 2005, 45:30-35.
17. Gasser A.B., Tieche M., Brunner K.W. Neurologic and cardiac toxicity following iv application of methotrexate. Cancer Treat. Rep. 1982, 66:1561-1562.
18. Gertz E.W., Wisneski J.A., Stanley W.C., Neese R.A. Myocardial substrate utilization during exercise in humans. Dual carbon-labeled carbohydrate isotope experiments. J. Clin. Invest. 1988, 82:2017-2025.
19. Goldoni D., Zhao Y., Green B.D., McDermott B.J., Collins A. Inward rectifier potassium channels in the HL-1 cardiomyocyte-derived cell line. J. Cell. Physiol. 2010, 225:751-756.
20. Gwathmey J.K., Tsaioun K., Hajjar R.J. Cardionomics: a new integrative approach for screening cardiotoxicity of drug candidates. Expert Opin. Drug Metab. Toxicol. 2009, 5:647-660.
21. Hans M.A., Heinzle E., Wittmann C. Free intracellular amino acid pools during autonomous oscillations in Saccharomyces cerevisiae. Biotechnol. Bioeng. 2003, 82:143-151.
22. Henney A.M. Who will take up the gauntlet? Challenges and opportunities for systems biology and drug discovery. EMBO Rep. 2009, 10(Suppl):S9-S13.
23. Henriques I.D., Aga D.S., Mendes P., O'Connor S.K., Love N.G. Metabolic footprinting: a new approach to identify physiological changes in complex microbial communities upon exposure to toxic chemicals. Environ. Sci. Technol. 2007, 41:3945-3951.
24. Hii J.T., Wyse D.G., Gillis A.M., Duff H.J., Solylo M.A., Mitchell L.B. Precordial QT interval dispersion as a marker of torsade de pointes. Disparate effects of class Ia antiarrhythmic drugs and amiodarone. Circulation 1992, 86:1376-1382.
25. Ho R.L., Lieu C.A. Systems biology: an evolving approach in drug discovery and development. Drugs R D 2008, 9:203-216.
26. Jensen J., Hyllner J., Bjorquist P. Human embryonic stem cell technologies and drug discovery. J. Cell. Physiol. 2009, 219:513-519.
27. Kaddurah-Daouk R., Kristal B.S., Weinshilboum R.M. Metabolomics: a global biochemical approach to drug response and disease. Annu. Rev. Pharmacol. Toxicol. 2008, 48:653-683.
28. Keene A.M., Balasubramanian R., Lloyd J., Shainberg A., Jacobson K.A. Multivalent dendrimeric and monomeric adenosine agonists attenuate cell death in HL-1 mouse cardiomyocytes expressing the A(3) receptor. Biochem. Pharmacol. 2010, 80:188-196.
29. Kettunen R., Huikuri H.V., Oikarinen A., Takkunen J.T. Methotrexate-linked ventricular arrhythmias. Acta Derm. Venereol. 1995, 75:391-392.
30. Keun H.C. Metabonomic modeling of drug toxicity. Pharmacol. Ther. 2006, 109:92-106.
31. Kim D.H., Jarvis R.M., Xu Y., Oliver A.W., Allwood J.W., Hampson L., Hampson I.N., Goodacre R. Combining metabolic fingerprinting and footprinting to understand the phenotypic response of HPV16 E6 expressing cervical carcinoma cells exposed to the HIV anti-viral drug lopinavir. Analyst 2010, 135:1235-1244.
32. 2+ signals in HL-1 atrial myocytes: possible role of IP3 receptor subtypes. Mol. Cells 2010, 29:387-395.
33. Kim Y., Ma A.G., Kitta K., Fitch S.N., Ikeda T., Ihara Y., Simon A.R., Evans T., Suzuki Y.J. Anthracycline-induced suppression of GATA-4 transcription factor: implication in the regulation of cardiac myocyte apoptosis. Mol. Pharmacol. 2003, 63:368-377.
34. Kromer J.O., Fritz M., Heinzle E., Wittmann C. In vivo quantification of intracellular amino acids and intermediates of the methionine pathway in Corynebacterium glutamicum. Anal. Biochem. 2005, 340:171-173.
35. Lazzara R. Antiarrhythmic drugs and torsade de pointes. Eur. Heart J. 1993, 14(Suppl):88-92.
36. Lipp P., Laine M., Tovey S.C., Burrell K.M., Berridge M.J., Li W., Bootman M.D. Functional InsP3 receptors that may modulate excitation-contraction coupling in the heart. Curr. Biol. 2000, 10:939-942.
37. Mayr M., Yusuf S., Weir G., Chung Y.L., Mayr U., Yin X., Ladroue C., Madhu B., Roberts N., De Souza A., Fredericks S., Stubbs M., Griffiths J.R., Jahangiri M., Xu Q., Camm A.J. Combined metabolomic and proteomic analysis of human atrial fibrillation. J. Am. Coll. Cardiol. 2008, 51:585-594.
38. McComb J.M., Logan K.R., Khan M.M., Geddes J.S., Adgey A.A. Amiodarone-induced ventricular fibrillation. Eur. J. Cardiol. 1980, 11:381-385.
39. McGettigan P., Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 2006, 296:1633-1644.
40. Monge C., Beraud N., Tepp K., Pelloux S., Chahboun S., Kaambre T., Kadaja L., Roosimaa M., Piirsoo A., Tourneur Y., Kuznetsov A.V., Saks V., Seppet E. Comparative analysis of the bioenergetics of adult cardiomyocytes and nonbeating HL-1 cells: respiratory chain activities, glycolytic enzyme profiles, and metabolic fluxes. Can. J. Physiol. Pharmacol. 2009, 87:318-326.
41. Mudge G.H., Mills R.M., Taegtmeyer H., Gorlin R., Lesch M. Alterations of myocardial amino acid metabolism in chronic ischemic heart disease. J. Clin. Invest. 1976, 58:1185-1192.
42. Nicholson J.K., Wilson I.D. Opinion: understanding 'global' systems biology: metabonomics and the continuum of metabolism. Nat. Rev. Drug Discov. 2003, 2(8):668-676.
43. Niklas J., Noor F., Heinzle E. Effects of drugs in subtoxic concentrations on the metabolic fluxes in human hepatoma cell line Hep G2. Toxicol. Appl. Pharmacol. 2009, 240:327-336.
44. Panchal A.R., Comte B., Huang H., Dudar B., Roth B., Chandler M., Des Rosiers C., Brunengraber H., Stanley W.C. Acute hibernation decreases myocardial pyruvate carboxylation and citrate release. Am. J. Physiol. Heart Circ. Physiol. 2001, 281:H1613-H1620.
45. Randle P.J., Newsholme E.A., Garland P.B. Regulation of glucose uptake by muscle. 8. Effects of fatty acids, ketone bodies and pyruvate, and of alloxan-diabetes and starvation, on the uptake and metabolic fate of glucose in rat heart and diaphragm muscles. Biochem. J. 1964, 93:652-665.
46. Robertson D.G. Metabonomics in toxicology: a review. Toxicol. Sci. 2005, 85:809-822.
47. Sabatine M.S., Liu E., Morrow D.A., Heller E., McCarroll R., Wiegand R., Berriz G.F., Roth F.P., Gerszten R.E. Metabolomic identification of novel biomarkers of myocardial ischemia. Circulation 2005, 112:3868-3875.
48. Sanders D.B., Larson D.F., Hunter K., Gorman M., Yang B. Comparison of tumor necrosis factor-alpha effect on the expression of iNOS in macrophage and cardiac myocytes. Perfusion 2001, 16:67-74.
49. Sanguinetti M.C., Mitcheson J.S. Predicting drug-hERG channel interactions that cause acquired long QT syndrome. Trends Pharmacol. Sci. 2005, 26:119-124.
50. Schimmel K.J., Richel D.J., van den Brink R.B., Guchelaar H.J. Cardiotoxicity of cytotoxic drugs. Cancer Treat. Rev. 2004, 30:181-191.
51. Schrickel J., Bielik H., Yang A., Schwab J.O., Shlevkov N., Schimpf R., Luderitz B., Lewalter T. Amiodarone-associated " torsade de pointes" Relevance of concomitant cardiovascular medication in a patient with atrial fibrillation and structural heart disease. Z. Kardiol. 2003, 92:889-892.
52. Schrickel J.W., Schwab J.O., Yang A., Bitzen A., Luderitz B., Lewalter T. " Torsade de pointes" in patients with structural heart disease and atrial fibrillation treated with amiodarone, beta-blockers, and digitalis. Pacing Clin. Electrophysiol. 2006, 29:363-366.
53. Senkus E., Jassem J. Cardiovascular effects of systemic cancer treatment. Cancer Treat. Rev. 2010.
54. Simunek T., Sterba M., Popelova O., Adamcova M., Hrdina R., Gersl V. Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron. Pharmacol. Rep. 2009, 61:154-171.
55. Stanley W.C., Lopaschuk G.D., Hall J.L., McCormack J.G. Regulation of myocardial carbohydrate metabolism under normal and ischaemic conditions. Potential for pharmacological interventions. Cardiovasc. Res. 1997, 33:243-257.
56. Stanley W.C., Recchia F.A., Lopaschuk G.D. Myocardial substrate metabolism in the normal and failing heart. Physiol. Rev. 2005, 85:1093-1129.
57. Taglialatela M., Castaldo P., Pannaccione A., Giorgio G., Genovese A., Marone G., Annunziato L. Cardiac ion channels and antihistamines: possible mechanisms of cardiotoxicity. Clin. Exp. Allergy 1999, 29(Suppl):182-189.
58. Tiziani S., Lodi A., Khanim F.L., Viant M.R., Bunce C.M., Gunther U.L. Metabolomic profiling of drug responses in acute myeloid leukaemia cell lines. PLoS ONE 2009, 4:e4251.
59. Waksman J.C., Brody A., Phillips S.D. Nonselective nonsteroidal antiinflammatory drugs and cardiovascular risk: are they safe?. Ann. Pharmacother. 2007, 41:1163-1173.
60. Wei L., Liao P., Wu H., Li X., Pei F., Li W., Wu Y. Metabolic profiling studies on the toxicological effects of realgar in rats by (1)H NMR spectroscopy. Toxicol. Appl. Pharmacol. 2009, 234:314-325.
61. West P.R., Weir A.M., Smith A.M., Donley E.L., Cezar G.G. Predicting human developmental toxicity of pharmaceuticals using human embryonic stem cells and metabolomics. Toxicol. Appl. Pharmacol. 2010, 247:18-27.
62. Westerhuis J., Hoefsloot H., Smit S., Vis D., Smilde A., van Velzen E., van Duijnhoven J., van Dorsten F. Assessment of PLSDA cross validation. Metabolomics 2008, 4:81-89.
63. White N.J. Cardiotoxicity of antimalarial drugs. Lancet Infect. Dis. 2007, 7:549-558.
64. White S.M., Constantin P.E., Claycomb W.C. Cardiac physiology at the cellular level: use of cultured HL-1 cardiomyocytes for studies of cardiac muscle cell structure and function. Am. J. Physiol. Heart Circ. Physiol. 2004, 286:H823-H829.
65. Wisneski J.A., Gertz E.W., Neese R.A., Gruenke L.D., Morris D.L., Craig J.C. Metabolic fate of extracted glucose in normal human myocardium. J. Clin. Invest. 1985, 76:1819-1827.
66. Xia M., Salata J.J., Figueroa D.J., Lawlor A.M., Liang H.A., Liu Y., Connolly T.M. Functional expression of L- and T-type Ca2+ channels in murine HL-1 cells. J. Mol. Cell. Cardiol. 2004, 36:111-119.
67. Yap Y.G., Camm A.J. The current cardiac safety situation with antihistamines. Clin. Exp. Allergy 1999, 29(Suppl):15-24.
68. Yarishkin O.V., Hwang E.M., Kim D., Yoo J.C., Kang S.S., Kim D.R., Shin J.H., Chung H.J., Jeong H.S., Kang D., Han J., Park J.Y., Hong S.G. Diclofenac, a non-steroidal anti-inflammatory drug, inhibits L-type Ca channels in neonatal rat ventricular cardiomyocytes. Korean J. Physiol. Pharmacol. 2009, 13:437-442.
69. Zhu J., Zhang B., Schadt E.E. A systems biology approach to drug discovery. Adv. Genet. 2008, 60:603-635.